{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:53:53Z","timestamp":1792601633522,"version":"4.5.0"},"reference-count":122,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T00:00:00Z","timestamp":1715904000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis (SJS\/TEN) are severe cutaneous adverse drug reactions (SCARs) characterized by widespread epithelial detachment and blistering, which affects the skin and mucocutaneous membranes. To date, therapeutic interventions for SJS\/TEN have focused on systematic suppression of the inflammatory response using high-dose corticosteroids or intravenous immunoglobulin G (IgG), for example. No targeted therapies for SJS\/TEN currently exist.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Though our understanding of the pathogenesis of SJS\/TEN has advanced from both an immunological and dermatological perspective, this knowledge is yet to translate into the development of new targeted therapies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Greater mechanistic insight into SJS\/TEN would potentially unlock new opportunities for identifying or repurposing targeted therapies to limit or even prevent epidermal injury and blistering.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/aci.0000000000000993","type":"journal-article","created":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T17:02:03Z","timestamp":1715878923000},"page":"218-227","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Greater mechanistic understanding of the cutaneous pathogenesis of Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis can shed light on novel therapeutic strategies: a comprehensive review"],"prefix":"10.1097","volume":"24","author":[{"given":"Emeka D.","family":"Ogiji","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK"},{"name":"Department of Pharmacology and Therapeutics, Ebonyi State University, Abakaliki, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nourah","family":"Aboheimed","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK"},{"name":"Department of Pharmacy Practice, Princess Nourah bint Abdulrahman University, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kehinde","family":"Ross","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calum","family":"Voller","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Siner","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca L.","family":"Jensen","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol E.","family":"Jolly","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel F.","family":"Carr","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,5,17]]},"reference":[{"key":"R1-20250527","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1056\/NEJM199512143332404","article-title":"Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis","volume":"333","author":"Roujeau","year":"1995","journal-title":"N Engl J Med"},{"key":"R2-20250527","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.jid.2017.01.031","article-title":"The epidemiology of Stevens-Johnson syndrome and toxic epidermal necrolysis in the UK","volume":"137","author":"Frey","year":"2017","journal-title":"J Invest Dermatol"},{"key":"R3-20250527","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.tox.2004.12.022","article-title":"Clinical heterogeneity of drug hypersensitivity","volume":"209","author":"Roujeau","year":"2005","journal-title":"Toxicology"},{"key":"R4-20250527","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1111\/epi.14591","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs: an analysis of the US Food and Drug Administration Adverse Event Reporting System","volume":"59","author":"Borrelli","year":"2018","journal-title":"Epilepsia"},{"key":"R5-20250527","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaad.2007.08.036","article-title":"Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel","volume":"58","author":"Halevy","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"R6-20250527","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1001\/jamadermatol.2022.6378","article-title":"Worldwide prevalence of antibiotic-associated Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"159","author":"Lee","year":"2023","journal-title":"JAMA Dermatol"},{"key":"R7-20250527","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1021\/tx5005248","article-title":"Systems pharmacological analysis of drugs inducing Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"28","author":"Hur","year":"2015","journal-title":"Chem Res Toxicol"},{"key":"R8-20250527","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.burns.2015.12.001","article-title":"Burn unit care of Stevens Johnson syndrome\/toxic epidermal necrolysis: a survey","volume":"42","author":"Le","year":"2016","journal-title":"Burns"},{"key":"R9-20250527","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1097\/BCR.0B013E318148C8AC","article-title":"DRG 272: does it provide adequate burn center reimbursement for the care of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis?","volume":"28","author":"Kagan","year":"2007","journal-title":"J Burn Care Res"},{"key":"R10-20250527","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/j.bjps.2016.01.034","article-title":"UK guidelines for the management of Stevens-Johnson syndrome\/toxic epidermal necrolysis in adults 2016","volume":"69","author":"Creamer","year":"2016","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"R11-20250527","doi-asserted-by":"crossref","first-page":"603","DOI":"10.4103\/0378-6323.191134","article-title":"Guidelines for the management of Stevens-Johnson syndrome\/toxic epidermal necrolysis: An Indian perspective","volume":"82","author":"Gupta","year":"2016","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R12-20250527","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.jaad.2020.02.066","article-title":"Society of Dermatology Hospitalists supportive care guidelines for the management of Stevens-Johnson syndrome\/toxic epidermal necrolysis in adults","volume":"82","author":"Seminario-Vidal","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"R13-20250527","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2340\/00015555-0214","article-title":"Dexamethasone pulse therapy for Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"87","author":"Kardaun","year":"2007","journal-title":"Acta Derm Venereol"},{"key":"R14-20250527","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.dsi.2017.04.004","article-title":"Efficacy of cyclosporine for the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: systemic review and meta-analysis","volume":"35","author":"Chen","year":"2017","journal-title":"Dermatol Sin"},{"key":"R15-20250527","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/jamadermatol.2023.0035","article-title":"Evaluation of plasmapheresis vs immunoglobulin as first treatment after ineffective systemic corticosteroid therapy for patients with Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"159","author":"Miyamoto","year":"2023","journal-title":"JAMA Dermatol"},{"key":"R16-20250527","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1111\/all.15608","article-title":"Intravenous immunoglobulins, cyclosporine, and best supportive care in epidermal necrolysis: diverse effects on systemic inflammation","volume":"78","author":"Schmidt","year":"2022","journal-title":"Allergy"},{"key":"R17-20250527","doi-asserted-by":"crossref","first-page":"e12832","DOI":"10.1111\/dth.12832","article-title":"Rapid remission of Stevens-Johnson syndrome by combination therapy using etanercept and intravenous immunoglobulin and a review of the literature","volume":"32","author":"Wang","year":"2019","journal-title":"Dermatol Ther"},{"key":"R18-20250527","first-page":"CD013130","article-title":"Systemic interventions for treatment of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS\/TEN overlap syndrome","volume":"3","author":"Jacobsen","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"R19-20250527","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s40264-019-00825-2","article-title":"Mechanisms of severe cutaneous adverse reactions: recent advances","volume":"42","author":"Bell\u00f3n","year":"2019","journal-title":"Drug Saf"},{"key":"R20-20250527","doi-asserted-by":"crossref","first-page":"588063","DOI":"10.3389\/fphar.2021.588063","article-title":"Current pharmacogenetic perspective on Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"12","author":"Cheng","year":"2021","journal-title":"Front Pharmacol"},{"key":"R21-20250527","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S1081-1206(10)60789-2","article-title":"Pathogenesis and recent therapeutic trends in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"97","author":"Khalili","year":"2006","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R22-20250527","doi-asserted-by":"crossref","first-page":"eaax2398","DOI":"10.1126\/scitranslmed.aax2398","article-title":"Neutrophils initiate and exacerbate Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"13","author":"Kinoshita","year":"2021","journal-title":"Sci Transl Med"},{"key":"R23-20250527","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008227","article-title":"An annexin A1;FPR1 interaction contributes to necroptosis of keratinocytes in severe cutaneous adverse drug reactions","volume":"6","author":"Saito","year":"2014","journal-title":"Sci Transl Med"},{"key":"R24-20250527","doi-asserted-by":"crossref","first-page":"E3261","DOI":"10.3390\/nu12113261","article-title":"Cellular function of annexin A1 protein mimetic peptide Ac2-26 in human skin keratinocytes HaCaT and fibroblast detroit 551 cells","volume":"12","author":"Kim","year":"2020","journal-title":"Nutrients"},{"key":"R25-20250527","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1001\/archderm.1997.03890430055008","article-title":"Epidermal apoptotic cell death in erythema multiforme and Stevens-Johnson syndrome: contribution of perforin-positive cell infiltration","volume":"133","author":"Inachi","year":"1997","journal-title":"Arch Dermatol"},{"key":"R26-20250527","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1067\/mai.2002.120563","article-title":"Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity","volume":"109","author":"Posadas","year":"2002","journal-title":"J Allergy Clin Immunol"},{"key":"R27-20250527","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/nm.1884","article-title":"Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"14","author":"Chung","year":"2008","journal-title":"Nat Med"},{"key":"R28-20250527","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jaad.2010.04.042","article-title":"Rapid immunochromatographic test for serum granulysin is useful for the prediction of Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"65","author":"Fujita","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"R29-20250527","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jaci.2004.04.034","article-title":"Involvement of CCL27-CCR10 interactions in drug-induced cutaneous reactions","volume":"114","author":"Tapia","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"R30-20250527","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1007\/s13555-023-00928-w","article-title":"Biologic TNF-\u03b1 inhibitors for Stevens\u2013Johnson Syndrome, toxic epidermal necrolysis, and TEN-SJS overlap: a study-level and patient-level meta-analysis","volume":"13","author":"Cao","year":"2023","journal-title":"Dermatol Ther"},{"key":"R31-20250527","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1172\/JCI93349","article-title":"Randomized, controlled trial of TNF-alpha antagonist in CTL-mediated severe cutaneous adverse reactions","volume":"128","author":"Wang","year":"2018","journal-title":"J Clin Invest"},{"key":"R32-20250527","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1159\/000525752","article-title":"Severe toxic epidermal necrolysis and drug reaction with eosinophilia and systemic symptoms overlap syndrome treated with benralizumab: a case report","volume":"14","author":"Zeller","year":"2022","journal-title":"Case Rep Dermatol"},{"key":"R33-20250527","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.jid.2016.11.034","article-title":"Interleukin-15 is associated with severity and mortality in Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"137","author":"Su","year":"2017","journal-title":"J Invest Dermatol"},{"key":"R34-20250527","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.3390\/biomedicines10081868","article-title":"IL-15\/IL-15R\u03b1 in SJS\/TEN: relevant expression of IL15 and IL15RA in affected skin","volume":"10","author":"Bell\u00f3n","year":"2022","journal-title":"Biomedicines"},{"key":"R35-20250527","doi-asserted-by":"crossref","first-page":"8705","DOI":"10.1073\/pnas.92.19.8705","article-title":"Tyrosine phosphorylation and activation of STAT5, STAT3, and Janus kinases by interleukins 2 and 15","volume":"92","author":"Johnston","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R36-20250527","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s13555-023-00892-5","article-title":"A review on the safety of using JAK inhibitors in dermatology: clinical and laboratory monitoring","volume":"13","author":"Samuel","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"R37-20250527","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s41927-022-00287-7","article-title":"Efficacy and safety of JAK inhibitors in the treatment of psoriasis and psoriatic arthritis: a systematic review and meta-analysis","volume":"6","author":"Sarabia","year":"2022","journal-title":"BMC Rheumatol"},{"key":"R38-20250527","first-page":"40","article-title":"Overview of safety, efficacy, and patient counseling for ruxolitinib in treating atopic dermatitis","volume":"21","author":"Mancuso-Stewart","year":"2023","journal-title":"Skinmed"},{"key":"R39-20250527","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13601-018-0199-6","article-title":"Diverse expression of TNF-alpha and CCL27 in serum and blister of Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"8","author":"Wang","year":"2018","journal-title":"Clin Transl Allergy"},{"key":"R40-20250527","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nm0202-157","article-title":"CCL27\u2013CCR10 interactions regulate T cell\u2013mediated skin inflammation","volume":"8","author":"Homey","year":"2002","journal-title":"Nat Med"},{"key":"R41-20250527","doi-asserted-by":"crossref","first-page":"5277","DOI":"10.1016\/j.bmcl.2016.09.047","article-title":"N-Arylsulfonyl-\u03b1-amino carboxamides are potent and selective inhibitors of the chemokine receptor CCR10 that show efficacy in the murine DNFB model of contact hypersensitivity","volume":"26","author":"Abeywardane","year":"2016","journal-title":"Bioorg Med Chem Lett"},{"key":"R42-20250527","first-page":"236","article-title":"Serum IFN-\u03b3-inducible chemokines CXCL9 and CXCL10 are elevated in nonimmediate drug hypersensitivity reactions","volume":"34","author":"Wang","year":"2016","journal-title":"Asian Pacific J Allergy Immunol"},{"key":"R43-20250527","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007811","article-title":"CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo","volume":"6","author":"Rashighi","year":"2014","journal-title":"Sci Transl Med"},{"key":"R44-20250527","doi-asserted-by":"crossref","first-page":"e5263","DOI":"10.1371\/journal.pone.0005263","article-title":"Atorvastatin reduces plasma levels of chemokine (CXCL10) in patients with Crohn's disease","volume":"4","author":"Grip","year":"2009","journal-title":"PLoS One"},{"key":"R45-20250527","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/377446a0","article-title":"Activation of the apoptotic protease CPP32 by cytotoxic T-cell-derived granzyme B","volume":"377","author":"Darmon","year":"1995","journal-title":"Nature"},{"key":"R46-20250527","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s004030050234","article-title":"The role of granzyme B-expressing CD8-positive T cells in apoptosis of keratinocytes in lichen planus","volume":"289","author":"Shimizu","year":"1997","journal-title":"Arch Dermatol Res"},{"key":"R47-20250527","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1093\/jac\/dki460","article-title":"Glycosaminoglycans inhibit the antibacterial activity of LL-37 in biological fluids","volume":"57","author":"Bara\u0144ska-Rybak","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"R48-20250527","doi-asserted-by":"crossref","first-page":"e0183542","DOI":"10.1371\/journal.pone.0183542","article-title":"LL-37 causes cell death of human nasal epithelial cells, which is inhibited with a synthetic glycosaminoglycan","volume":"12","author":"Thomas","year":"2017","journal-title":"PLoS One"},{"key":"R49-20250527","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1001\/archderm.1997.03890430055008","article-title":"Epidermal apoptotic cell death in erythema multiforme and Stevens-Johnson syndrome. Contribution of perforin-positive cell infiltration","volume":"133","author":"Inachi","year":"1997","journal-title":"Arch Dermatol"},{"key":"R50-20250527","doi-asserted-by":"crossref","first-page":"e200117","DOI":"10.1212\/NXI.0000000000200117","article-title":"Effects of a small-molecule perforin inhibitor in a mouse model of CD8\u200aT cell\u2013mediated neuroinflammation","volume":"10","author":"Gonzalez-Fierro","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R51-20250527","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/j.1365-2133.2006.07398.x","article-title":"Expression of cytokines and chemokine receptors in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"155","author":"Caproni","year":"2006","journal-title":"Br J Dermatol"},{"key":"R52-20250527","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1002\/j.1460-2075.1990.tb07433.x","article-title":"Cyclosporin A suppresses the expression of the interleukin 2 gene by inhibiting the binding of lymphocyte-specific factors to the IL-2 enhancer","volume":"9","author":"Randak","year":"1990","journal-title":"EMBO J"},{"key":"R53-20250527","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2147\/JIR.S160964","article-title":"A meta-analysis of cyclosporine treatment for Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"11","author":"Ng","year":"2018","journal-title":"J Inflamm Res"},{"key":"R54-20250527","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1111\/cea.12145","article-title":"In vitro drug causality assessment in Stevens\u2013Johnson syndrome \u2013 alternatives for lymphocyte transformation test","volume":"43","author":"Porebski","year":"2013","journal-title":"Clin Exp Allergy"},{"key":"R55-20250527","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1067\/mjd.2002.120473","article-title":"Increased interleukin 10, tumor necrosis factor \u03b1, and interleukin 6 levels in blister fluid of toxic epidermal necrolysis","volume":"47","author":"Correia","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"R56-20250527","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.jaad.2022.01.039","article-title":"Inhibition of tumor necrosis factor improves conventional steroid therapy for Stevens-Johnson syndrome\/toxic epidermal necrolysis in a cohort of patients","volume":"86","author":"Ao","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"R57-20250527","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1159\/000100880","article-title":"Serum levels of the Th1 promoter IL-12 and the Th2 chemokine TARC are elevated in erythema multiforme and Stevens-Johnson syndrome\/toxic epidermal necrolysis and correlate with soluble Fas ligand expression: an immunoenzymatic study from the Italian Group of Immunopathology","volume":"214","author":"Quaglino","year":"2007","journal-title":"Dermatology"},{"key":"R58-20250527","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1172\/JCI0215950","article-title":"IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells","volume":"110","author":"Parihar","year":"2002","journal-title":"J Clin Invest"},{"key":"R59-20250527","doi-asserted-by":"crossref","first-page":"8576","DOI":"10.4049\/jimmunol.181.12.8576","article-title":"IL-12 produced by dendritic cells augments CD8+ T cell activation through the production of the chemokines CCL1 and CCL17","volume":"181","author":"Henry","year":"2008","journal-title":"J Immunol"},{"key":"R60-20250527","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"New Engl J Med"},{"key":"R61-20250527","doi-asserted-by":"crossref","first-page":"1076029620950831","DOI":"10.1177\/1076029620950831","article-title":"The role of IL-13, IL-15 and granulysin in the pathogenesis of Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"27","author":"Sadek","year":"2021","journal-title":"Clin Appl Thromb Hemost"},{"key":"R62-20250527","first-page":"184","article-title":"Serum interleukin-13 levels are increased in patients with Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis but not in those with erythema multiforme","volume":"158","author":"Quaglino","year":"2008","journal-title":"Br J Dermatol"},{"key":"R63-20250527","doi-asserted-by":"crossref","first-page":"1165098","DOI":"10.3389\/fmed.2023.1165098","article-title":"The hidden sentinel of the skin: an overview on the role of interleukin-13 in atopic dermatitis","volume":"10","author":"Napolitano","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"R64-20250527","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/jamadermatol.2020.0079","article-title":"Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical trial","volume":"156","author":"Guttman-Yassky","year":"2020","journal-title":"JAMA Dermatol"},{"key":"R65-20250527","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"New Engl J Med"},{"key":"R66-20250527","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1084\/jem.191.5.771","article-title":"Reversible defects in natural killer and memory CD8\u200aT cell lineages in interleukin 15-deficient mice","volume":"191","author":"Kennedy","year":"2000","journal-title":"J Exp Med"},{"key":"R67-20250527","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1182\/blood-2012-08-450585","article-title":"Phase 1 trial of IL-15 trans presentation blockade using humanized Mik\u03b21 mAb in patients with T-cell large granular lymphocytic leukemia","volume":"121","author":"Waldmann","year":"2013","journal-title":"Blood"},{"key":"R68-20250527","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/ced.13213","article-title":"Serum IL-17 in patients with erythema multiforme or Stevens-Johnson syndrome\/toxic epidermal necrolysis drug reaction, and correlation with disease severity","volume":"42","author":"Morsy","year":"2017","journal-title":"Clin Exp Dermatol"},{"key":"R69-20250527","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/prd.12083","article-title":"Basic biology and role of interleukin-17 in immunity and inflammation","volume":"69","author":"Zenobia","journal-title":"Periodontol"},{"key":"R70-20250527","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1056\/NEJMoa1109017","article-title":"Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis","volume":"366","author":"Papp","year":"2012","journal-title":"N Engl J Med"},{"key":"R71-20250527","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa2102388","article-title":"Bimekizumab versus adalimumab in plaque psoriasis","volume":"385","author":"Warren","year":"2021","journal-title":"New Engl J Med"},{"key":"R72-20250527","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis \u2014 results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"New Engl J Med"},{"key":"R73-20250527","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jaip.2018.05.037","article-title":"Differential expression of alarmins: IL-33 as a candidate marker for early diagnosis of toxic epidermal necrolysis","volume":"7","author":"Adachi","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R74-20250527","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/intimm\/dxn060","article-title":"IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells","volume":"20","author":"Smithgall","year":"2008","journal-title":"Int Immunol"},{"key":"R75-20250527","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1007\/s11030-021-10359-4","article-title":"Discovery of small molecular inhibitors for interleukin-33\/ST2 protein-protein interaction: a virtual screening, molecular dynamics simulations and binding free energy calculations","volume":"26","author":"Mai","year":"2022","journal-title":"Mol Divers"},{"key":"R76-20250527","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.jaci.2008.06.013","article-title":"Increased soluble Fas ligand levels in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis preceding skin detachment","volume":"122","author":"Murata","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"R77-20250527","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1046\/j.1523-1747.2003.12014.x","article-title":"Fas ligand in pemphigus sera induces keratinocyte apoptosis through the activation of caspase-8","volume":"120","author":"Puviani","year":"2003","journal-title":"J Invest Dermatol"},{"key":"R78-20250527","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1111\/1346-8138.16847","article-title":"TNF-\u03b1 induced extracellular release of keratinocyte high-mobility group box 1 in Stevens-Johnson syndrome\/toxic epidermal necrolysis: biomarker and putative mechanism of pathogenesis","volume":"50","author":"Nwikue","year":"2023","journal-title":"J Dermatol"},{"key":"R79-20250527","doi-asserted-by":"crossref","first-page":"538","DOI":"10.2119\/molmed.2014.00183","article-title":"High systemic levels of the cytokine-inducing HMGB1 isoform secreted in severe macrophage activation syndrome","volume":"20","author":"Palmblad","year":"2015","journal-title":"Mol Med"},{"key":"R80-20250527","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2119\/molmed.2010.00031","article-title":"Immunomodulatory drugs regulate HMGB1 release from activated human monocytes","volume":"16","author":"Schierbeck","year":"2010","journal-title":"Mol Med"},{"key":"R81-20250527","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/joim.12309","article-title":"The functions of HMGB1 depend on molecular localization and posttranslational modifications","volume":"276","author":"Andersson","year":"2014","journal-title":"J Intern Med"},{"key":"R82-20250527","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1189\/jlb.1212662","article-title":"The many faces of HMGB1: molecular structure-functional activity in inflammation, apoptosis, and chemotaxis","volume":"93","author":"Yang","year":"2013","journal-title":"J Leukocyte Bio"},{"key":"R83-20250527","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/bjd.17610","article-title":"Serum and blister-fluid elevation and decreased epidermal content of high-mobility group box 1 protein in drug-induced Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"181","author":"Carr","year":"2019","journal-title":"Br J Dermatol"},{"key":"R84-20250527","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1111\/bjd.13162","article-title":"The serum level of HMGB1 (high mobility group box 1 protein) is preferentially high in drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms","volume":"171","author":"Fujita","year":"2014","journal-title":"Br J Dermatol"},{"key":"R85-20250527","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/archdermatol.2011.239","article-title":"High-mobility group box 1 protein (HMGB1) as a novel diagnostic tool for toxic epidermal necrolysis and Stevens-Johnson syndrome","volume":"147","author":"Nakajima","year":"2011","journal-title":"Arch Dermatol"},{"key":"R86-20250527","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/bjd.17610","article-title":"Serum and blister-fluid elevation and decreased epidermal content of HMGB1 protein in drug-induced Stevens Johnson syndrome\/toxic epidermal necrolysis","volume":"181","author":"Carr","year":"2019","journal-title":"Brit J Dermatol"},{"key":"R87-20250527","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13045-020-00950-x","article-title":"HMGB1 in inflammation and cancer","volume":"13","author":"Wang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"R88-20250527","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1084\/jem.20141318","article-title":"MD-2 is required for disulfide HMGB1-dependent TLR4 signaling","volume":"212","author":"Yang","year":"2015","journal-title":"J Exp Med"},{"key":"R89-20250527","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1084\/jem.20111739","article-title":"HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4","volume":"209","author":"Schiraldi","year":"2012","journal-title":"J Exp Med"},{"key":"R90-20250527","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1073\/pnas.2434651100","article-title":"Reversing established sepsis with antagonists of endogenous high-mobility group box 1","volume":"101","author":"Yang","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R91-20250527","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.bbagrm.2009.11.003","article-title":"The role of HMGB1 in the pathogenesis of rheumatic disease","volume":"1799","author":"Andersson","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"R92-20250527","first-page":"7","article-title":"Increased dermal expression of chromatin-associated protein HMGB1 and concomitant T-cell expression of the DNA RAGE in patients with psoriasis vulgaris","volume":"9","author":"Strohbuecker","year":"2019","journal-title":"Psoriasis (Auckl)"},{"key":"R93-20250527","doi-asserted-by":"crossref","first-page":"737","DOI":"10.5551\/jat.31088","article-title":"HMGB1 modulates the Treg\/Th17 ratio in atherosclerotic patients","volume":"23","author":"Ding","year":"2016","journal-title":"J Atheroscler Thromb"},{"key":"R94-20250527","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/jvh.12152","article-title":"Enhanced high-mobility group box 1 (HMGB1) modulates regulatory T cells (Treg)\/T helper 17 (Th17) balance via toll-like receptor (TLR)-4-interleukin (IL)-6 pathway in patients with chronic hepatitis B","volume":"21","author":"Li","year":"2014","journal-title":"J Viral Hepat"},{"key":"R95-20250527","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1089\/jir.2010.0019","article-title":"The potential effect and mechanism of high-mobility group box 1 protein on regulatory T cell-mediated immunosuppression","volume":"31","author":"Zhang","year":"2011","journal-title":"J Interferon Cytokine Res"},{"key":"R96-20250527","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.chembiol.2007.03.007","article-title":"Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities","volume":"14","author":"Mollica","year":"2007","journal-title":"Chem Biol"},{"key":"R97-20250527","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1111\/j.1365-2133.2009.09627.x","article-title":"Differential gene expression in drug hypersensitivity reactions: induction of alarmins in severe bullous diseases","volume":"162","author":"Bellon","year":"2010","journal-title":"Br J Dermatol"},{"key":"R98-20250527","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s00403-004-0506-z","article-title":"Possible involvement of gelatinase A (MMP2) and gelatinase B (MMP9) in toxic epidermal necrolysis or Stevens-Johnson syndrome","volume":"296","author":"Gaultier","year":"2004","journal-title":"Arch Dermatol Res"},{"key":"R99-20250527","doi-asserted-by":"crossref","first-page":"1023.e7","DOI":"10.1016\/j.jid.2022.11.024","article-title":"TNF-\u03b1-mediated keratinocyte expression and release of matrix metalloproteinase 9: putative mechanism of pathogenesis in stevens\u2013johnson syndrome\/toxic epidermal necrolysis","volume":"143","author":"Olsson-Brown","year":"2023","journal-title":"J Invest Dermatol"},{"key":"R100-20250527","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/pde.13612","article-title":"Clinical studies evaluating abametapir lotion, 0.74%, for the treatment of head louse infestation","volume":"35","author":"Bowles","year":"2018","journal-title":"Pediatr Dermatol"},{"key":"R101-20250527","doi-asserted-by":"crossref","first-page":"106008","DOI":"10.1016\/j.oraloncology.2022.106008","article-title":"Evaluation of the matrix metalloproteinase 9 (MMP9) inhibitor Andecaliximab as an Antiinvasive therapeutic in Head and neck squamous cell carcinoma","volume":"132","author":"Allen","year":"2022","journal-title":"Oral Oncol"},{"key":"R102-20250527","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/ptr.3055","article-title":"Boswellia frereana (frankincense) suppresses cytokine-induced matrix metalloproteinase expression and production of pro-inflammatory molecules in articular cartilage","volume":"24","author":"Blain","year":"2010","journal-title":"Phytother Res"},{"key":"R103-20250527","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.2337\/db17-1238","article-title":"MicroRNA-129 and -335 promote diabetic wound healing by inhibiting Sp1-mediated MMP-9 expression","volume":"67","author":"Wang","year":"2018","journal-title":"Diabetes"},{"key":"R104-20250527","doi-asserted-by":"crossref","first-page":"3134","DOI":"10.1016\/j.xphs.2020.06.021","article-title":"Development of brain targeting peptide based MMP-9 inhibiting nanoparticles for the treatment of brain diseases with elevated MMP-9 activity","volume":"109","author":"Islam","year":"2020","journal-title":"J Pharm Sci"},{"key":"R105-20250527","doi-asserted-by":"crossref","first-page":"578129","DOI":"10.3389\/fimmu.2020.578129","article-title":"Neutrophil extracellular traps tied to rheumatoid arthritis: points to ponder","volume":"11","author":"Song","year":"2020","journal-title":"Front Immunol"},{"key":"R106-20250527","first-page":"33","article-title":"The role of NETosis in systemic lupus erythematosus","volume":"1","author":"Salemme","year":"2019","journal-title":"J Cell Immunol"},{"key":"R107-20250527","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nrneph.2016.71","article-title":"The role of neutrophils and NETosis in autoimmune and renal diseases","volume":"12","author":"Gupta","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"R108-20250527","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev-bioeng-071516-044610","article-title":"Sulfation of glycosaminoglycans and its implications in human health and disorders","volume":"19","author":"Soares da Costa","year":"2017","journal-title":"Annu Rev Biomed Eng"},{"key":"R109-20250527","doi-asserted-by":"crossref","first-page":"543","DOI":"10.4049\/jimmunol.0803959","article-title":"LL-37 complexation with glycosaminoglycans in cystic fibrosis lungs inhibits antimicrobial activity, which can be restored by hypertonic saline","volume":"183","author":"Bergsson","year":"2009","journal-title":"J Immunol"},{"key":"R110-20250527","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1080\/1547691X.2021.1905754","article-title":"Impact of mono-culture vs. co-culture of keratinocytes and monocytes on cytokine responses induced by important skin sensitizers","volume":"18","author":"Karri","year":"2021","journal-title":"J Immunotoxicol"},{"key":"R111-20250527","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/1523-1747.ep12335935","article-title":"The co-culture of dermal fibroblasts with human epidermal keratinocytes induces increased prostaglandin E2 production and cyclooxygenase 2 activity in fibroblasts","volume":"109","author":"Sato","year":"1997","journal-title":"J Invest Dermatol"},{"key":"R112-20250527","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1177\/1535370217710637","article-title":"In vitro psoriasis models with focus on reconstructed skin models as promising tools in psoriasis research","volume":"242","author":"Desmet","year":"2017","journal-title":"Exp Biol Med (Maywood)"},{"key":"R113-20250527","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3390\/pharmaceutics4010026","article-title":"Tissue engineered human skin equivalents","volume":"4","author":"Zhang","year":"2012","journal-title":"Pharmaceutics"},{"key":"R114-20250527","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1177\/1535370217710637","article-title":"In vitro psoriasis models with focus on reconstructed skin models as promising tools in psoriasis research","volume":"242","author":"Desmet","year":"2017","journal-title":"Exp Biol Med (Maywood)"},{"key":"R115-20250527","doi-asserted-by":"crossref","first-page":"E1670","DOI":"10.3390\/ijms20071670","article-title":"Infiltration of T cells into a three-dimensional psoriatic skin model mimics pathological key features","volume":"20","author":"Lorthois","year":"2019","journal-title":"Int J Mol Sci"},{"key":"R116-20250527","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3390\/bioengineering8110148","article-title":"The importance of mimicking dermal-epidermal junction for skin tissue engineering: a review","volume":"8","author":"Aleemardani","year":"2021","journal-title":"Bioengineering (Basel)"},{"key":"R117-20250527","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/jdv.15301","article-title":"JAK1\/3 inhibition preserves epidermal morphology in full-thickness 3D skin models of atopic dermatitis and psoriasis","volume":"33","author":"Clarysse","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R118-20250527","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1158\/1535-7163.MCT-15-0394","article-title":"A novel fully humanized 3D skin equivalent to model early melanoma invasion","volume":"14","author":"Hill","year":"2015","journal-title":"Molecular cancer therapeutics"},{"key":"R119-20250527","doi-asserted-by":"crossref","first-page":"434.e1","DOI":"10.1016\/j.jaci.2012.09.014","article-title":"Stevens-Johnson syndrome\/toxic epidermal necrolysis mouse model generated by using PBMCs and the skin of patients","volume":"131","author":"Saito","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"R120-20250527","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1016\/j.jid.2017.05.031","article-title":"Inhibitor of apoptosis proteins (IAPs) limit RIPK1-mediated skin inflammation","volume":"137","author":"Anderton","year":"2017","journal-title":"J Invest Dermatol"},{"key":"R121-20250527","doi-asserted-by":"crossref","first-page":"778269","DOI":"10.3389\/fbioe.2021.778269","article-title":"Sensitive colorimetric detection of interleukin-6 via lateral flow assay incorporated silver amplification method","volume":"9","author":"Rahbar","year":"2021","journal-title":"Front Bioeng Biotechnol"},{"key":"R122-20250527","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jaip.2017.11.023","article-title":"SJS\/TEN 2017: building multidisciplinary networks to drive science and translation","volume":"6","author":"White","year":"2018","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["Current Opinion in Allergy &amp; Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ACI.0000000000000993","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T18:04:00Z","timestamp":1748369040000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/ACI.0000000000000993"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,17]]},"references-count":122,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/aci.0000000000000993","relation":{},"ISSN":["1528-4050","1473-6322"],"issn-type":[{"value":"1528-4050","type":"print"},{"value":"1473-6322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,17]]}}}